☆ 4.6 Article

Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial

FRONTIERS IN MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Surgery

Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients

Nassim Kamar et al.

Summary: The immunogenicity of the SARS-CoV-2 vaccine was enhanced by a third dose. A retrospective study on solid organ transplant patients found that two-thirds of them developed anti-SARS-CoV-2 antibodies after three doses, but one-third remained weak or non-protected. Antibody concentrations and protection levels decreased between 1 and 3 months after vaccination.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Markus Hoffmann et al.

Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.

CELL (2022)

Add to Collection

Article Medicine, General & Internal

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients A Randomized Clinical Trial

Roman Reindl-Schwaighofer et al.

Summary: Less than 50% of kidney transplant recipients developed antibodies against the SARS-CoV-2 spike protein after 2 doses of an mRNA vaccine. A third dose of either mRNA or vector vaccine increased antibody response in 39% of KTRs without prior immune response, but neutralizing antibodies and T-cell response remained low. Triple immunosuppression, longer time after transplant, and torque teno virus plasma levels were associated with vaccine response. Local pain was higher with mRNA vaccine, but systemic symptoms were similar between groups.

JAMA INTERNAL MEDICINE (2022)

Add to Collection

Letter Infectious Diseases

Antibody titers and protection against a SARS-CoV-2 infection

Chloe Dimeglio et al.

JOURNAL OF INFECTION (2022)

Add to Collection

Editorial Material Urology & Nephrology

COVID-19 vaccination in kidney transplant recipients

Sophie Caillard et al.

Summary: Kidney transplant recipients, due to therapeutic immunosuppression, have impaired immune responses to the COVID-19 mRNA vaccine, necessitating a personalized intensified vaccination approach for better protection.

NATURE REVIEWS NEPHROLOGY (2021)

Add to Collection

Article Immunology

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Qian He et al.

Summary: Our study demonstrated that utilizing a heterologous prime-boost strategy with different combinations of COVID-19 vaccine candidates can enhance neutralizing antibody levels and T cell responses, providing new insights for vaccine development and application in controlling the SARS-CoV-2 pandemic.

EMERGING MICROBES & INFECTIONS (2021)

Add to Collection

Article Surgery

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Ayelet Grupper et al.

Summary: Only 37.5% of transplant recipients developed a positive immune response to the Pfizer vaccine, with lower antibody levels, and factors associated with null immune response include older age, high-dose corticosteroids use, triple immunosuppression maintenance, and regimen with mycophenolate.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Alexandra J. Spencer et al.

Summary: The study suggests that heterologous vaccination with a self-amplifying RNA vaccine and an adenoviral vectored vaccine against SARS-CoV-2 in mice leads to higher antibody responses and superior cellular immune responses compared to homologous vaccination regimens.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Surgery

Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients

Tina Schmidt et al.

Summary: This study found that solid organ transplant recipients had lower levels of SARS-CoV-2-specific antibodies and T cells compared to controls after homologous or heterologous vaccination. However, heterologous vaccination showed promise in improving immune responses in transplant recipients, with higher induction of antibodies and CD4 T cells.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Article Immunology

The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays

Maria Infantino et al.

Summary: The study found that results of different commercial quantitative anti-SARS-CoV-2 assays are not interchangeable, emphasizing the importance of using the same method for individual immune monitoring. Additionally, values expressed as BAU/ml showed reduced between-assays variability compared to values expressed as AU/ml.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Tina Schmidt et al.

Summary: In healthy adults, vaccination with an mRNA vaccine as a booster, regardless of the initial vaccine, resulted in higher levels of spike-specific antibodies and T cells compared to booster vaccination with ChAdOx1 nCov-19. Heterologous vaccination with ChAdOx1 nCoV-19 followed by an mRNA vaccine induced strong immune responses with acceptable reactogenicity, showing similar or better effects than homologous mRNA vaccine regimens.

NATURE MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

David Hillus et al.

Summary: This study evaluated the reactogenicity and immunogenicity of homologous and heterologous COVID-19 vaccinations, with results showing that heterologous immunization has good immunogenicity and tolerability.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition

Arne Sattler et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.